World Vape Day: BAT Review Highlights 10 Years of Scientific Evidence on Vaping



  • Numerous scientific studies show that the complete switch to vaping with high quality products reduced the health risks
  • compared to smoking, contrary to many consumer beliefs
  • Study data indicates vaping products may provide an alternative to smokers who otherwise would not quit
  • Review supports important role of vaping products in tobacco harm reduction
  • Reinforce the importance of BAT’s unique consumer-centric model and how we are reducing the impact of our business on health and building A Better Tomorrow â„¢ through our multi-category approach

To mark World Vape Day, BAT today released a comprehensive review of the scientific evidence for vaping products (electronic cigarettes), their potential health effects, and their role in reducing the harm of tobacco.

This review shows that, over the past decade, the number of people who mistakenly believe that vaping is as harmful or more harmful than smoking conventional cigarettes has increased in the UK, Europe and the US. same period showing that vaping products manufactured to quality standards pose less of a health risk than cigarettes. *

According to demographic modeling studies cited in the review, a significant reduction in premature deaths could be achieved if current smokers switched exclusively to vaping rather than continuing to smoke. These modeling studies use demographics and simulations to project health-related outcomes associated with the long-term risks of smoking versus steam use over time.

Dr David O’Reilly, Director of Scientific Research at BAT, said: “This paper is a comprehensive summary of over 300 peer-reviewed scientific papers and other evidence published by approximately 50 institutions over the past year. decade.

“The scientific evidence is clear – but consumer misperceptions remain. In England and the United States, only one in three adults know there is scientific evidence available, including from leading public health authorities, which support the conclusion that vaping is less harmful than smoking.

“The reality is that many prominent public health authorities have reported that vaping is less harmful than smoking, and that this harm reduction potential can be maximized if smokers who would otherwise continue to smoke switched exclusively to smoking. use of steam products.

“We hope this article will be used as a resource by public health authorities and support adult smokers seeking to understand the extent of scientific evidence that exists to inform their choices.”

“Reducing the impact of our business on health is at the heart of our goal – creating a better future by offering the widest range of reduced risk alternatives to cigarettes *,” continued David O’Reilly. “That’s why we aim to have 50 million consumers of our new category products, which include our vaping product line, Vuse, by 2030.”

This review highlights that vaping products can effectively compete with combustible cigarettes in delivering nicotine and the sensory pleasure smokers seek. Therefore, access to high quality, widely tested and well regulated vaping products is crucial. However, vaping will only be seen as a compelling alternative to smoking if public health institutions unambiguously and accurately inform smokers that switching entirely to vaping can reduce their health risks.

The document also reviews current regulations for steam products and notes that these regulations largely relate only to labeling, ingredients and taxation – but not manufacturing standards. This has resulted in widely varying product quality standards globally.

The review highlights the need for consistent product manufacturing regulations and the universal adoption of robust product stewardship standards by manufacturers with the goal of increasing public confidence in vaping.


Find out more by clicking on these links:

* Summary of scientific review

* Full review article: Camacho, Oscar M., Ebajemito, James K., Coburn, Steven, Prasad, Krishna, Costigan, Sandra and Murphy, James J .. “Evidence from the Scientific Assessment of Electronic Cigarettes and their Role in Tobacco Harm Reduction ” Contributions to research on tobacco and nicotine, flight. 30, No. 2, 2021, pages 63-108. https: // /article /ten.2478 /cttr-2021-0007

Notes to Editors

The white paper reviewed over a decade of scientific data and peer-reviewed studies from multiple sources around the world to understand and assess different aspects of e-cigarettes and their role in tobacco harm reduction, including the importance of design, testing and adherence to manufacturing standards.

Our review assesses published studies on how the sensory aspects of steam products, including the aromas and visibility of steam aerosols, play an important role in this product acceptability for former risk-seeking smokers. reduced.

  • alternatives to cigarettes and for current adult vapers who want to avoid resuming smoking. Data indicates that adult vapers prefer e-cigarettes that offer a variety of flavors and that this variety makes vapor products a more viable alternative to continued smoking.

    About BAT

    BAT is a leading, multi-category consumer goods company whose goal is to build a better future by reducing the impact of its activity on health by offering a greater choice of pleasant and less risky products for consumers. adults. The company continues to make it clear that combustible cigarettes pose serious health risks, and the only way to avoid those risks is to not start or quit smoking. BAT encourages those who would otherwise continue to smoke to switch completely to scientifically proven and reduced risk alternatives.

  • . To achieve this, BAT is transforming itself into a truly consumer-centric, multi-category consumer product company. BAT employs more than 53,000 people and operates in more than 180 countries, with 11 million outlets and 45 factories in 43 markets. The company’s strategic portfolio consists of its global cigarette brands and a growing line of reduced risk products
  • New category of tobacco and nicotine products and traditional non-combustible tobacco products. These include steam, tobacco heaters, modern oral products including tobacco-free nicotine packets, as well as traditional oral products such as snus and wet snuff. In 2020, we had 13.5 million consumers of our non-combustible products, an increase of 3 million from the previous year. BAT Group generated revenue of £ 25.8 billion in 2020 and operating profit of £ 9.9 billion.
  • Based on weight of evidence and assuming complete smoking cessation. These products are not without risk and are addictive. Our products as sold in the United States, including Vuse, Velo, Grizzly, Kodiak and Camel Snus, are subject to Food and Drug Administration (FDA) regulation and no reduced risk claims will be made with respect to these products. without FDA clearance.

    Forward-looking statements

    This press release contains certain forward-looking statements, including “forward-looking” statements made within the meaning of the United States Private Securities Litigation Reform Act of 1995. These statements are often, but not always, made using such words or phrases. that “believe”, “anticipate”, “could”, “may”, “would”, “should,” “intend”, “plan”, “potential”, “predict”, “will”, “s ‘expect’, ‘estimate’, ” project ‘,’ positioned ‘,’ strategy ‘,’ outlook ‘,’ target ‘and the like. These include statements regarding the ambition of our target client, the objectives of income from new categories and our ESG objectives.

    All of these forward-looking statements involve estimates and assumptions that are subject to risks, uncertainties and other factors. The expectations reflected in this press release are believed to be reasonable, but they may be affected by a wide range of variables that could cause actual results to differ materially from those currently expected. A review of the reasons why actual results and developments may differ materially from the expectations disclosed or implied in the forward-looking statements can be found by referring to the information contained in the sections “Forward-looking statements” and “Principal risks of the group” in the Report. Annual 2020 and British American Tobacco plc (BAT) Form 20-F.

    Additional information regarding these and other factors can be found in documents filed by BAT with the United States Securities and Exchange Commission (“SEC”), including the Annual Report on Form 20-F and Current Reports. on Form 6-K, which can be obtained free of charge. bill on the SEC website, http: // and BAT annual reports, which can be obtained free of charge from the British American Tobacco website http: //

    Past performance is no guarantee of future performance and those requiring advice should consult an independent financial advisor. Forward-looking statements reflect the knowledge and information available on the date of preparation of this press release and BAT does not undertake to update or revise these forward-looking statements, whether as a result of new information, future events or other. Readers are cautioned not to place undue reliance on these forward-looking statements.

    Ask for information

    Press office

    Anna vickerstaff

    +44 (0) 20 7845 2888 (24 hours) | @BATplc

    Investor Relations

    Mike Nightingale: +44 (0) 20 7845 1180

    Victoria Buxton: +44 (0) 20 7845 2012

    William Houston: +44 (0) 20 7845 1138

    John Harney: +44 (0) 20 7845 1263

  • Warning: AAAS and EurekAlert! are not responsible for the accuracy of any press releases posted on EurekAlert! by contributing institutions or for the use of any information via the EurekAlert system.


    Leave A Reply

    Your email address will not be published.